Pancreatic Cancer Research

ResearcherSapporo Medical UniversityActive in the last 2 years

Yasutoshi Kimura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7790-9250; OpenAlex author ID A5045415586. Sources: OpenAlex.

Their work

Papers
28 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
111
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 2 papers · 2014: none · 2015: 4 papers · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 3 papers · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers

Papers 28

  1. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  2. The Role of Claudin-1 in Enhancing Pancreatic Cancer Aggressiveness and Drug Resistance via Metabolic Pathway Modulation. Co-author DOI 10.3390/cancers17091469↗
  3. Role of preoperative circulating tumor DNA in predicting occult metastases in resectable and borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.3748/wjg.v31.i32.109383↗
  4. Predictors of occult metastases in potentially Resectable pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.sopen.2024.07.010↗
  5. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan P… Co-author DOI 10.1007/s00535-023-01988-7↗
  6. HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-022-14094-0↗
  7. Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer. Co-author DOI 10.3390/ijms231911521↗
  8. Conversion pancreaticoduodenectomy with dual arterial reconstructions for locally advanced pancreatic cancer: Case report and literature review. Co-author DOI 10.1016/j.ijscr.2021.105692↗
  9. Perioperative Predictors of Early Recurrence for Resectable and Borderline-Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers13102285↗
  10. Amplification of mutant KRAS G12D in a patient with advanced metastatic pancreatic adenocarcinoma detected by liquid biopsy: A case report. First author DOI 10.3892/mco.2021.2334↗
  11. Tricellular tight junction protein LSR/angulin-1 contributes to the epithelial barrier and malignancy in human pancreatic cancer cell line. Co-author DOI 10.1007/s00418-019-01821-4↗
  12. Glucose-Dependent FOXM1 Promotes Epithelial-to-Mesenchymal Transition Via Cellular Metabolism and Targeting Snail in Human Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001485↗
  13. Clinical Outcomes of Biliary Drainage during a Neoadjuvant Therapy for Pancreatic Cancer: Metal versus Plastic Stents. Co-author DOI 10.5009/gnl18573↗
  14. Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging: Results from a multicenter… Co-author DOI 10.1002/ags3.12272↗
  15. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderl… Co-author DOI 10.1016/j.ijrobp.2019.07.004↗
  16. Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma. Co-author DOI 10.1111/cas.14106↗
  17. Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine. Co-author DOI 10.1007/s00262-018-2217-x↗
  18. MicroRNA-196b is an independent prognostic biomarker in patients with pancreatic cancer. Co-author DOI 10.1093/carcin/bgx013↗
  19. Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis? Co-author DOI 10.1007/s00595-015-1120-8↗
  20. Associations between polymorphisms in folate-metabolizing genes and pancreatic cancer risk in Japanese subjects. Co-author DOI 10.1186/s12876-016-0503-7↗
  21. Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway. Co-author DOI 10.1002/prp2.196↗
  22. A case of curatively resected gastric wall implantation of pancreatic cancer caused by endoscopic ultrasound-guided fine-needle aspiration. Co-author DOI 10.1055/s-0034-1377592↗
  23. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Co-author DOI 10.18632/oncotarget.3109↗
  24. A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells. Co-author DOI 10.3892/ijo.2015.2880↗
  25. Protein kinase Cα inhibitor protects against downregulation of claudin-1 during epithelial-mesenchymal transition of pancreatic cancer. Co-author DOI 10.1093/carcin/bgt057↗
  26. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Co-author DOI 10.1111/cas.12046↗
  27. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinic… Co-author DOI 10.1007/s00280-012-1822-1↗
  28. Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells. Co-author DOI 10.1002/jcb.23095↗

Closest collaborators

The 25 strongest of 111 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masafumi Imamura · 15 shared papers, 2011–2025 · strength 1.55
  2. Ichiro Takemasa · 10 shared papers, 2017–2025 · strength 1.18
  3. Masayo Motoya · 8 shared papers, 2017–2025 · strength 0.91
  4. Daisuke Kyuno · 8 shared papers, 2011–2025 · strength 0.87
  5. Makoto Yoshida · 4 shared papers, 2019–2025 · strength 0.57
  6. Tsuyoshi Hayashi · 6 shared papers, 2015–2023 · strength 0.55
  7. Takashi Kojima · 6 shared papers, 2011–2025 · strength 0.54
  8. Siew‐Kee Low · 3 shared papers, 2021–2025 · strength 0.50
  9. Takumi Konno · 4 shared papers, 2015–2025 · strength 0.48
  10. Satoshi Hirano · 5 shared papers, 2019–2022 · strength 0.48
  11. Takeshi Murakami · 2 shared papers, 2024–2025 · strength 0.41
  12. Toru Nakamura · 4 shared papers, 2019–2022 · strength 0.38
  13. Koichi Hirata · 8 shared papers, 2011–2019 · strength 0.34
  14. Kazunori Watanabe · 2 shared papers, 2022–2025 · strength 0.33
  15. Sohei Satoi · 2 shared papers, 2023–2025 · strength 0.31
  16. Daisuke Hashimoto · 2 shared papers, 2023–2025 · strength 0.31
  17. Michiaki Unno · 2 shared papers, 2023–2025 · strength 0.31
  18. Tõru Nakamura · 2 shared papers, 2022–2025 · strength 0.30
  19. Fabio Pittella-Silva · 2 shared papers, 2021–2022 · strength 0.29
  20. Yusuke Nakamura · 2 shared papers, 2021–2022 · strength 0.29
  21. Akira Takasawa · 3 shared papers, 2011–2025 · strength 0.28
  22. Hiroshi Nakase · 2 shared papers, 2017–2024 · strength 0.26
  23. Makoto Osanai · 1 shared paper, 2025 · strength 0.22
  24. Takuro Kyuno · 2 shared papers, 2020 · strength 0.22
  25. Yoshihiko Hirohashi · 4 shared papers, 2013–2019 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.